Format

Send to

Choose Destination
Trop Med Int Health. 2010 Jul;15(7):811-8. doi: 10.1111/j.1365-3156.2010.02537.x. Epub 2010 May 11.

Evaluation of two commercially available ELISAs for the diagnosis of Japanese encephalitis applied to field samples.

Author information

1
Brain Infections Group, University of Liverpool, Liverpool, UK. pennylewthwaite@doctors.org.uk

Abstract

OBJECTIVE:

To compare two commercially available kits, Japanese Encephalitis-Dengue IgM Combo ELISA (Panbio Diagnostics) and JEV-CheX IgM capture ELISA (XCyton Diagnostics Limited), to a reference standard (Universiti Malaysia Sarawak - Venture Technologies VT ELISA).

METHODS:

Samples were obtained from 172/192 children presenting to a site in rural India with acute encephalitis syndrome.

RESULTS:

Using the reference VT ELISA, infection with Japanese encephalitis virus (JEV) was confirmed in 44 (26%) patients, with central nervous system infection confirmed in 27 of these; seven patients were dengue seropositive. Of the 121 remaining patients, 37 (31%) were JEV negative and 84 (69%) were JEV unknown because timing of the last sample tested was <10 day of illness or unknown. For patient classification with XCyton, using cerebrospinal fluid alone (the recommended sample), sensitivity was 77.8% (59.2-89.4) with specificity of 97.3% (90.6-99.2). For Panbio ELISA, using serum alone (the recommended sample), sensitivity was 72.5% (57.2-83.9) with specificity of 97.5% (92.8-99.1). Using all available samples for patient classification, sensitivity and specificity were 63.6% (95% CI: 48.9-76.2) and 98.4% (94.5-99.6), respectively, for XCyton ELISA and 75.0% (59.3-85.4) and 97.7% (93.3-99.2) for Panbio ELISA.

CONCLUSION:

The two commercially available ELISAs had reasonable sensitivities and excellent specificities for diagnosing JEV.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center